Nivolumab for the treatment of colorectal cancer.

abstract：:The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

journal_title：Expert review of anticancer therapy

authors： Camara-Clayette V,Hermine O,Ribrag V

更新日期：2012-09-01 00:00:00

abstract：:Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...

journal_title：Expert review of anticancer therapy

authors： Lewis S,Menon U

更新日期：2003-02-01 00:00:00

abstract：INTRODUCTION:The treatment of chronic myeloid leukemia (CML) has been drastically changed by the approval of tyrosine kinase inhibitors (TKIs). CML is now managed as a chronic disease requiring both long-term treatment and close molecular monitoring in the majority of patients. AREAS COVERED:Evidence suggests that in ...

journal_title：Expert review of anticancer therapy

authors： Stagno F,Breccia M,Di Raimondo F

更新日期：2020-12-01 00:00:00

abstract：:Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

journal_title：Expert review of anticancer therapy

authors： Popovtzer A,Eisbruch A

更新日期：2008-04-01 00:00:00

abstract：:Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

journal_title：Expert review of anticancer therapy

authors： Tsao CK,Gartrell BA,Oh WK,Galsky MD

更新日期：2012-12-01 00:00:00

abstract：:Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

journal_title：Expert review of anticancer therapy

authors： Kose MF,Meydanli MM,Tulunay G

更新日期：2006-03-01 00:00:00

abstract：:As with many human malignancies, pancreatic cancer is a complex genetic disorder. Several thousand disease-associated alterations on the DNA, mRNA, miRNA and protein levels have been reported to date. Some of these alterations, including a number of gatekeeper mutations, which are of pre-eminent importance for the ons...

journal_title：Expert review of anticancer therapy

authors： Buchholz M,Gress TM

更新日期：2009-10-01 00:00:00

abstract：:Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to expl...

journal_title：Expert review of anticancer therapy

authors： Soria F,Allasia M,Oderda M,Gontero P

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

journal_title：Expert review of anticancer therapy

authors： Tosoni A,Balestrini D,Brandes AA

更新日期：2017-05-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer-related deaths in the Western world. The lungs can be affected by a number of histologically diverse malignancies. Nonetheless, the vast majority of lung cancers are classified as non-small-cell lung cancer (NSCLC). Despite extensive research on different therapeutic regimens...

journal_title：Expert review of anticancer therapy

authors： Galluzzo P,Bocchetta M

更新日期：2011-04-01 00:00:00

abstract：:Bladder cancer is rare in patients below the age of 50 years, and most patients are in their 60s and 70s. Radical cystectomy is the preferred approach for patients with localized disease in most European countries and the USA, and evidence is growing in favor of neoadjuvant, platinum-based chemotherapy for patients at...

journal_title：Expert review of anticancer therapy

authors： Basso U,Bassi P,Sava T,Monfardini S

更新日期：2004-12-01 00:00:00

abstract：:Ca(2+) influx at critical points in the cell cycle is required for proliferation. This requirement is so ubiquitous that its occurrence is often treated as background noise. Yet without it, cells stop dividing, suggesting an obvious and potentially effective way to treat cancer. To control proliferation by controlling...

journal_title：Expert review of anticancer therapy

authors： Gray LS,Schiff D,Macdonald TL

更新日期：2013-05-01 00:00:00

abstract：:Since its first description nearly two centuries ago, melanoma has been a difficult disease to diagnose and treat. With the incidence and mortality rates slowly increasing, understanding this disease is more important than ever. Herein, the current diagnostic and treatment recommendations for melanoma of the head and ...

journal_title：Expert review of anticancer therapy

authors： Lentsch EJ,McMasters KM

更新日期：2003-10-01 00:00:00

abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (RCC). Drugs such as sorafenib, sunitinib and pazopanib act on the VEGF receptor pathway, but they can also inhibit other kinases, resulting in off-target toxicities. Tivozanib was developed due to its potency and selectivi...

journal_title：Expert review of anticancer therapy

authors： Wong HH,Eisen T

更新日期：2013-06-01 00:00:00

abstract：:Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleo...

journal_title：Expert review of anticancer therapy

authors： Robak T

更新日期：2008-07-01 00:00:00

abstract：:The role of neoadjuvant chemotherapy in muscle-invasive bladder cancer has been clarified by recent randomized studies and meta-analyses, which all showed that cisplatin-based, combination chemotherapy offers a significant survival advantage. Preoperative chemotherapy results in downstaging in a significant percentage...

journal_title：Expert review of anticancer therapy

authors： Bamias A,Dimopoulos MA

更新日期：2005-12-01 00:00:00

abstract：:According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...

journal_title：Expert review of anticancer therapy

authors： Gabriel EM,Jatoi I

更新日期：2012-02-01 00:00:00

abstract：:Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,James ND

更新日期：2002-12-01 00:00:00

abstract：:Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

journal_title：Expert review of anticancer therapy

authors： Ward JF,Blute ML

更新日期：2003-04-01 00:00:00

abstract：:Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

journal_title：Expert review of anticancer therapy

authors： Ghavamian R,Hakimi AA

更新日期：2009-12-01 00:00:00

abstract：:Atypical hyperplasia and lobular carcinoma in situ are rare proliferative breast lesions, growing inside ducts and terminal ducto-lobular units. They represent a marker of increased risk for breast cancer and a non-obligate precursor of malignancy. Evidence available on diagnosis and management is scarce. They are fre...

journal_title：Expert review of anticancer therapy

authors： Clauser P,Marino MA,Baltzer PA,Bazzocchi M,Zuiani C

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Cancer genome sequencing studies have discovered mutations in members of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex in nearly 25% of human cancers. The SWI/SNF complex, first discovered in S. cerevisiae, shows strong conservation from yeast to Drosophila to mammals, contains ...

journal_title：Expert review of anticancer therapy

authors： Orlando KA,Nguyen V,Raab JR,Walhart T,Weissman BE

更新日期：2019-05-01 00:00:00

abstract：:Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

journal_title：Expert review of anticancer therapy

authors： Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

更新日期：2014-01-01 00:00:00

abstract：INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...

journal_title：Expert review of anticancer therapy

authors： Buchanan T,Mutch D

更新日期：2019-01-01 00:00:00

abstract：:Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

journal_title：Expert review of anticancer therapy

authors： Micali G,Lacarrubba F,Bhatt K,Nasca MR

更新日期：2013-12-01 00:00:00

abstract：:Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and, thereby, improve the survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens ...

journal_title：Expert review of anticancer therapy

authors： Tyagi RK,Mangal S,Garg N,Sharma PK

更新日期：2009-01-01 00:00:00

abstract：:Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

journal_title：Expert review of anticancer therapy

authors： Reed AB,Parekh DJ

更新日期：2010-01-01 00:00:00

abstract：:Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

journal_title：Expert review of anticancer therapy

authors： Hussein MR,Baidas S

更新日期：2002-10-01 00:00:00

abstract：:Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorab...

journal_title：Expert review of anticancer therapy

authors： Rocco D,Della Gravara L,Battiloro C,Gridelli C

更新日期：2019-07-01 00:00:00

abstract：INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

journal_title：Expert review of anticancer therapy

authors： Greenwell IB,Flowers CR,Blum KA,Cohen JB

更新日期：2017-03-01 00:00:00